Drape Eric 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 7, 2023

Form 4

Period: 2023-03-03

Executive VP Global Operations

Transactions

Exercise/Conversion
Ordinary Shares
2023-03-04+11,940→ 123,439 total
Award
Restricted Share Units
2023-03-03+99,601→ 99,601 total
→ Ordinary Shares (99,601 underlying)
Exercise/Conversion
Ordinary Shares
2023-03-04+33,512→ 156,951 total
Exercise/Conversion
Ordinary Shares
2023-03-05+22,576→ 179,527 total
Exercise/Conversion
Restricted Share Units
2023-03-04−11,940→ 0 total
→ Ordinary Shares (11,940 underlying)
Exercise/Conversion
Restricted Share Units
2023-03-04−33,512→ 100,536 total
→ Ordinary Shares (33,512 underlying)
Exercise/Conversion
Restricted Share Units
2023-03-05−22,576→ 45,152 total
→ Ordinary Shares (22,576 underlying)

Footnotes (6)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.
[F4]Restricted share units were granted on March 4, 2019, with 11,940 vested on each of March 4, 2021, March 4, 2022, and March 4, 2023.
[F5]Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026.
[F6]Restricted share units were granted on March 5, 2021, with 22,576 vested on March 5, 2022 and March 5, 2023, and 22,576 vesting on each of March 5, 2024 and March 5, 2025.

Documents

1 file